Compare NISN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NISN | CANF |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.4M |
| IPO Year | 2016 | N/A |
| Metric | NISN | CANF |
|---|---|---|
| Price | $0.98 | $4.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | 33.0K | ★ 88.0K |
| Earning Date | 04-28-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $238,745,633.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $3.36 |
| 52 Week High | $9.33 | $46.60 |
| Indicator | NISN | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 22.30 | 64.75 |
| Support Level | $1.05 | $3.87 |
| Resistance Level | $1.17 | $4.55 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 2.94 | 23.87 |
NiSun International Enterprise Development Group Co Ltd is a provider of supply chain solutions and integrated financial services. Nisun is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, it is engaged in delivering supply chain solutions, and supply chain trading services to its customers across different industries. The company also provides financial solutions to small and mid-sized enterprises within the supply chain ecosystem. Using its fintech platforms, it provides various financing options, including supply chain financing, trade financing, and receivables financing. Geographically, its operations are predominantly focused on markets within the People's Republic of China.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.